Grifols, S.A. (ADR)
General ticker "GRFS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $5.8B (TTM average)
Grifols, S.A. (ADR) does not follow the US Stock Market performance with the rate: -16.4%.
Estimated limits based on current volatility of 1.8%: low 7.35$, high 7.62$
Factors to consider:
- Company pays dividends (annually): last record date 2026-07-02, amount 0.11$ (Y1.44%)
- Total employees count: 25247 as of 2025
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.37$, 13.13$]
- 2026-12-31 to 2027-12-31 estimated range: [10.02$, 15.27$]
Financial Metrics affecting the GRFS estimates:
- Positive: with PPE of 11.1 at the end of fiscal year the price was neutral
- Positive: 15.80 < Operating profit margin, % of 16.43
- Positive: 15.29 < Operating cash flow per share per price, % of 19.00
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Positive: 1.88 < Return on assets ratio (scaled to [-100,100]) of 2.37
- Positive: 25.20 < Shareholder equity ratio, % of 26.68 <= 34.41
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
Short-term GRFS quotes
Long-term GRFS plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | €7,212.38MM | €7,227.05MM |
| Operating Expenses | €6,020.37MM | €6,039.83MM |
| Operating Income | €1,192.02MM | €1,187.22MM |
| Non-Operating Income | €-748.02MM | €-596.49MM |
| Interest Expense | €773.15MM | €600.33MM |
| R&D Expense | €384.04MM | €358.28MM |
| Income(Loss) | €444.00MM | €590.73MM |
| Taxes | €231.19MM | €110.46MM |
| Net Income(Loss)* | €156.92MM | €386.13MM |
| Stockholders Equity | €5,883.73MM | €5,268.76MM |
| Inventory | €3,560.10MM | €3,294.60MM |
| Assets | €21,405.24MM | €19,749.59MM |
| Operating Cash Flow | €902.17MM | €1,005.68MM |
| Capital expenditure | €371.37MM | €254.54MM |
| Investing Cash Flow | €886.67MM | €-556.15MM |
| Financing Cash Flow | €-1,358.71MM | €-508.12MM |
| Earnings Per Share** | €0.23 | €0.57 |
| Ordinary share to ADR | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.